The presence of pre-existing HLA antibodies in blood donors has been implicated in Transfusion-Related Acute Lung Injury (TRALI) and TRALI-like transfusion reactions in the recipients of blood products from sensitized donors. TRALI is a syndrome that is described as a spectrum of clinical symptoms that occur very rapidly (usually in 1-2 hours) following transfusion with blood products. Occurring in a small number of patients that receive blood products, it remains the leading cause of transfusion-related deaths reported to the Food and Drug Administration.
DonorScreen-HLA Class I and Class II assay
Your laboratory’s solution for testing blood products for HLA antibodies demonstrates your commitment to keeping blood transfusions safe.
Immucor’s DonorScreen-HLA® Class I and Class II assay offers a reliable, accurate and cost effective screening for HLA antibodies to help maintain your donor base while improving patient outcomes. Our assay has been specifically designed to detect these antibodies in blood donors using the STRATEC BIOMEDICAL AG® GEMINI (GEMINI) automated ELISA processing instrument.1